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To investigate the functional heterogeneity of mouse mast 
cells, we extracted and purified cutaneous and peritoneal 
mast cells from 10- to 18-week-old BALB/c mice and com-
pared their responses to secretagogues. Cutaneous mast cells 
(CMC) were extracted from mouse ears after digestion with 
hyaluronidase and collagenase in MEM containing 25% fetal 
calf serum and purified on a discontinuous Percoll gradient. 
The histamine content of cells obtained from the 30/ 40% 
interface was 1.0 ± 0.1 pg/ cell (mean± SE), with a mast-
cell purity of 68.6 ± 4.4% and a viability of> 93%. Perito-
neal mast cells (PM C) were obtained by lavage with modified 
Tyrode's buffer followed by purification on 22.5% and 3-
9% metrizamide gradients. The histamine content of cells 
was 12.2 ± 0.8 pg/cell, with a mast-cell purity of 95 .9 ± 
0.6% and a viability of> 95%. Histamine release induced by 
A23187 from CMC peaked at 3.0 j.lM A23187 (19.1 ± 
4.2%), at 3.0min (22.3±2.3%), and at 30oC (17.6 "± 
2.6%). In contrast, histamine release from PMC peaked at 
8.0 j.lM of A23187 (49.4 ± 12.1 %) and at 15.0 min (48.5 ± 
M ast cells are well know~ as c:itical partic~pants ~n a variety of important b10log1c processes mcludmg inflammatory reactions, cytotoxicity, angiogen-esis, immunoregulation, and fibrosis [1]. BALB/c mice are a commonly used animal model for the 
study of cutaneous inflammation; however, their cutaneous mast 
cells have not been well characterized. This study was designed to 
extract, purify, and functionally characterize cutaneous mast. cells 
( CMC) from BALB j c mice. In view of the known heterogene1~ of 
mucosal and connective tissue mast cells (2-10], we exammed 
whether such heterogeneity exists in CMC and pe~itoneal mast cells 
(PM C) of BALB/c mice, both of wh1ch are con~1dered to be .con-
nective tissue mast cells [11]. Therefore, the functlonal properties of 
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Abbreviations: 
A23187: calcium ionophore 
12.2% ). Release of histamine from PMC was observed at al( 
the temperatures tested from 22 to 45 o C. Histamine releas~ 
from CMC and PMC induced by A23187 was calcium de, 
pendent. Histamine release induced by compound 48 /8n 
from CMC peaked at 0.5 J.lg/ml of compound 48/8n 
(23.0 ± 7.4%) and at 5.0 min incubation (16.3 ± 2.0%)
1 
whereas release from PMC peaked at 10.0 J.lg/ml (31.9 ~ 
2.6%); release from PMC was similar at all the time point' 
examined (1-15 min) . Histamine release induced by sub\ 
stance P (SP) from both CMC and PMC peaked at 5.0 .U!v\ 
(18.8 ± 6.6% and 12.6 ± 3.7%, respectively); however, th~ 
maximal release from CMC occurred at 3.0 min (18.2 ~ 
3.2%) and from PMC at 30.0 min (11.4 ± 2.0%). SP-in, 
duced histamine release from CMC was calcium dependent, 
whereas release from PMC was only partially inhibited by 
EDT A. This study demonstrated that functional heterogene-
ity exists between these two populations of mast cells.] Inves~ 
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extracted and partially purified CMC and PMC are compared, usin~ 
calcium ionophore A23187, compound 48/80, and substance P as, 
secretagogues. 
MATERIALS AND METHODS 
Reagents The following chemicals were obtained from th~ 
sources indicated: sodium chloride, gelatin, heparin, bovine sei1lllj 
albumin, calcium ionophore (A23187), compound 48/80, sub, 
stance P (SP), dimethylsulfoxide (DMSO), N -2-hydroxy-ethylpi, 
perazine-N'-2-ethanesulfonic acid (HEPES), hyaluronidase (typ~ 
1), Tritot:t-100, ethylenediaminetetraacetic acid (EDTA) (Sigm' 
Chemical Co., St. Louis, MO); sodium bicarbonate, dextrose, potas, 
sium chloride, sodium phosphate monobasic, calcium chloride, 
BSA: bovine serum albumin 
CMC: cutaneous mast cells 
EDT A: ethylenediaminetetraacetic acid 
FCS: fetal calf serum 
HEPES: N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid 
HEPES-BSS: HEPES-buffered salt solution 
MEM: Eagle's minimum essential medium 
PMC: peritoneal mast cells 
SP: substance P 
TGD: Tyrode's buffer containing 1.80 mM calcium, 1.05 mM 
magnesium, 0.1% gelatin, and 0.002% deoxyribonuclease 
TGD=: TGD free of calcium and magnesium 
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magnesium chloride (Fisher Scientific Co., Springfield, NJ); metri-
zamide (Accurate Chemical and Scientific Corp., Westbury, NY); 
fetal calf serum (FCS) (heat inactivated), Eagle's minimum essential 
medium (MEM) containing 25 mM HEPES and L-glutamine 
(Gibco, Grand Island, NY); Percoll (Pharmacia, Inc., Piscataway, 
NJ); bovine pancreas deoxyribonuclease (Calbiochem Corp., La 
J oil a, CA); and collagenase, type 1 (Worthington Biochemical, 
Freehold, NJ). HEPES-buffered salt solution (HEPES-BSS), pH 
7.2, containing NaCI, 137 mM; HEPES 10 mM; D-glucose, 
5 mlv1; KCI, 2.7 mM; NaH2P04 , 0.4 mM; MgCl2 , 0.5 mM; and 
CaC12 , 1.8 mM, was used in the purification and activation of 
CMC. 
Animals Female BALB/c mice, 10- to 18-week-old, were used 
(Taconic Laboratories, Germantown, NY). 
Purification ofCMC CMC were dispersed from mouse ears by 
a modification of previously described enzymatic techniques [8, 12]. 
Mice were sacrificed by cervical dislocation; the ears were removed 
and immediately placed in MEM at room temperature. The ears 
were then pulled apart into two leaves, cut into fragments of ap-
proximately 1.0 mm with scissors, and washed with MEM contain-
ing 25% FCS (MEM/FCS). They were incubated for 60 min at 
37" C in the same buffer (1 g tissue/30 ml buffer) containing colla-
genase, 1.5 mg/ml, and hyaluronidase, 0.5 mg/ml. The tissue was 
pressed against the sides of the culture tube every 15 min thereby 
facilitating digestion. Cells dispersed by this procedure were sepa-
rated from tissue by filtration through Nytex Swiss nylon gauze 
(20 ,urn) (Tetko Inc., Lancaster, NY), washed twice in MEM/FCS, 
and sedimented by centrifugation at 500 X g for 5 min at room 
temperature. Undigested tissue was subjected to a second identical 
digestion procedure, and cells obtained from each digestion were 
pooled. 
Percoll density medium was rendered isotonic by the addition of 
10% final volume of 10 times concentrated HEPES-BSS containing 
deoxyribonuclease, 0.1 mgjml. Discontinuous density gradients 
were prepared in 15 ml conical centrifuge tubes (Fisher) by sequen-
tial layering of 2-ml samples of each of 60%, 50%, 40%, 30%, and 
20% isotonic Percoll previously prepared by dilution with 5% 
MEM/FCS. Samples of 2 ml of freshly dispersed skin cells in 5% 
MEM/FCS containing 15 to 20 X 106 nucleated cells were layered 
on the gradients, which were then centrifuged at 500 X g for 
10 min at room temperature. Cells were harvested at the interfaces 
between Percoll density layers of aspiration with a 1.0-ml pasteur 
pipette (Fisher), and the corresponding fractions from each gradient 
were pooled, diluted with four volumes of 25% MEM/FCS, and 
centrifuged at 500 X g for 5 min at room temperature. The recov-
ered cells were washed in 25% MEM/FCS and suspended for quan-
titation and assessment of viability. In pilot studies (Table I), the 
highest mast-cell purity was observed at the 30/40% interface; 
therefore, cells from this interface were used in all the functional 
experiments. Prior to activation, the cells were washed once with 
25% MEM/FCS and resuspended in HEPES-BSS with 5% FCS. In 
experiments to evaluate the requirement for calcium, the latter 
Table I. Purification of Murine-Dispersed Cutaneous Mast 
Cells by Discontinuous Percoll Gradient Centrifugation• 
Percent Percoll 
Concenration 
Untreated dispersate 
< 20 
20/30 
30/40 
40/50 
50/60 
>60 
.. 0 =5. 
I Mean± SE. 
Percent Mast-Cell 
Purity 
32.8 ± 7.96 
16.6 ± 0.9 
28.6 ± 3.7 
68.6 ± 4.4 
46.2 ± 7.5 
25.0 ± 4.8 
11.4 ± 2.8 
Mast-Cell Yield 
(X 106 Cells/Mouse) 
5.09 ± 1.16 
0.22 ± 0.1 
0.18 ± 0.0 
1.04 ± 0.2 
0.30 ± 0.1 
0.14 ± 0.0 
0.02 ± 0.0 
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buffer was replaced by HEPES-BSS lacking calcium and containing 
1.0 mM EDTA. In experiments in which calcium reconstitution 
was performed, calcium was added to HEPES-BSS lacking calcium, 
and the reconstituted buffer was then used for washing and suspen-
sion of the cells. 
Purification of PMC The animals were sacrificed by cervical 
dislocation. Six ml ofTyrode's buffer lacking calcium and magne-
sium containing 0.1% gelatin and 0.005% heparin were injected 
into the peritoneal cavities. The peritoneal lavage was collected in 
polypropylene tubes and centrifuged at 200 X g for 10 min at room 
temperature. The cell pellet was resuspended in TGD= and filtered 
through Nytex Swiss nylon gauze (20 ,um). Two-ml suspensions of 
cells (5-1 0 mice/2 ml) were layered on 22.5% (w /v) metrizamide 
in TGD= and centrifuged at 500 X g for 15 min at room tempera-
ture. After washing twice in TGD=, the cells were resuspended in 
5-6 ml TGD= and layered on 30 ml3-9% (w/v) continuous me-
trizamide gradients in TGD= and were centrifuged at 35 X g for 
12 min at room temperature. The recovered cells were washed 
twice in TGD= and were suspended for quantitation and assessment 
of viability [13] . Prior to activation, the cells were washed once with 
and resuspended in TGD with 0.5% BSA. In experiments to study 
the requirement for calcium, TGD= containing 1.0 mM EDTA 
was used in these latter two steps. 
Mast-Cell Quantitation and Viability Determination Mast-
cell numbers were determined under light microscopy after staining 
with 0.01 o/o toludine blue in ethyl alcohol. The purity of mast cells 
was calculated by dividing the number of mast cells by the total 
nucleated cells in each experiment. The viability was assessed by 
trypan blue exclusion. 
Activation ofCMC and PMC Dose-response and kinetic stud-
ies with various secretagogues were carried out at 3 7 o C in duplicate. 
All cells and buff~rs were premcubated for 5 min at 37"C prior to 
use. In studies with CMC, HEPES-BSS containing 5% FCS was 
used. Three X 104 CMC in 450 ,ul was added to each tube, followed 
by the addition of buffer and dilutions of the secretagogue to give a 
final volume of 500 ,ul. In studies with PMC, TGD buffer with 
0.5% BSA was used. Two hundred and twenty five microliters of 
PMC (6.7 X 104 cells/ml) was added to each tube, followed by the 
addition of buffer and dilutions of the secretagogue to yield a final 
volume of 450 ,ul. Based on the results of kinetic studies, in dose-re-
sponse experiments, the CMC and PMC were exposed to the secre-
tagogues for 3 min and 10 min. respectively. Reactions were termi-
nated by the addition of 200 ,ul of ice-cold buffer, and the 
immersion of th~ tubes in an ice-water bath. After centrifugation at 
200 X g for 5 mm at room temperature, supernatant fractions were 
separated; the cell pellets were suspended in ice-cold buffer in a 
volume equal to that of the original reaction mixture, and were 
disrupted by sonication. 
Histamine Assay Histamine levels in the supernatant fractions 
and cell pellets were determined using a double-isotope radioen-
zyme assay described previously [14,15] . The results were expressed 
as percent net histamine release, defined as percent stimulated re-
lease (histamine in supernatant/histamine in both supernatant and 
pellet) minus percent background release. Each value represents the 
mean± SE. 
RESULTS 
Purification and Characterization of CMC and PMC As 
shown in Table II, CMC and PMC of a purity of 68.6 ± 4.4% and 
95.9 ± 0.6%, respectively, were obtained. The histamine content 
of PMC was approximately 12 times higher than that of CMC 
(12.2 ± 0.8 pgjcell versus 1.0 ± 0.1 pg/cell), whereas the yield of 
CMCwas25timeshigherthanthatofPMC(1 X 106 CMC/ mouse 
versus 4 X 104 PMC/mouse). 
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Table II. Characteristics of Extracted Mast Cells 
Purity (% ± SE) 
Histamine (pg/cell ± SE) 
Yield (cells/mouse, X 106) 
Viability(%) 
Spontaneous histamine release (o/o ± SE) 
• Peritoneal mast cells. 
• Cutaneous mast cells. 
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Figure 1. Dose-response analysis of A23187 -induced histamine release 
from mast cells of BALB/c mice. {A) Release from CMC with a 3-min 
incubation (n = 3). {B) Release from PMC with a 10-min incubation (n = 
3 - 5) . 
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Figure 2. Time course of A23187-induced histamine release from mast 
cells of BALB/c mice. {A) Release from CMC induced by 3.0 f.JM of 
A23187 (n = 3). (B) Release from PMC induced by 4.0 ,uM of A23187 
(n = 3-5) . 
Response ofCMC and PMC to Calcium Ionophore (A23187) 
Dose-Respor1se Analysis: For CMC, a maximum net histamine re-
le~se of 19.1 ± 4.2% was ob.served at 3.0 ,uM A23187 (Fig 1A). 
H1stamme release by PMC (F1g 1B) continued to increase in a dose-
dependent fashion over the concentration range tested (0.4-8.0 
,uM), with a net release of 49.4 ± 12.1% noted at 8.0 ,uM A23187. 
Time-Course Analysis: To investigate the time course of histamine 
release from CMC and PMC in response to A23187, parallel exper-
iments were performed by incubating CMC with 3.0 ,uM A23187 
and PMC with 4.0 ,uM A23187. CMC had a maximum net hista-
mine release of22.3 ± 2.3% at 3.0 min (Fig. 2A). The time course 
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of histamine release from PMC was slower, reaching a maximum 
net release of 48.5 ± 12.2% at the longest incubation time tested 
(15 min). 
Temperature Dependence: For CMC, the maximum net histamine 
release of 17.6 ± 2.6% occurred in 30oC (Fig 3A). Histamine re-
lease from PMC was of the same magnitude over the temperature 
range tested from 22 to 45 °C (Fig 3B). 
Requirement for Calcium: To determine the requirement for extra-
cellular calcium, experiments were done in which CMC were incu-
bated for 3 min with A23187 (0 to 10.0 J.lM) in the presence or 
absence of 1.0 mM EDT A. EDT A suppressed A23187 -induced his-
tamine release from CMC by 51% to 88% (Table III) . This require-
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Figure 3. Temperature dependence of A23187-induced histamine release 
from mast cells ofBALB/c mice. (A) Release from CMC induced by 3.0 ,uM 
of A23187, using a 3-min incubation (n = 7). (B) Release from PMC in-
duced by 4.0 J.lM of A23187, using a 10-min incubation (n = 2). 
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Table Ill. Effect of EDTA (1.0 mM) on Percent Net Histamine 
Release From Cutaneous Mast Cells Induced by A23187• 
A23187 
(,uM) 
1.0 
3.0 
8.0 
10.0 
Percent Net Histamine Release 
Without EDTA 
7.2 ± 1.6 
18.5 ± 4.8 
10.8 ± 2.3 
8.3 ± 7.8 
WithEDTA 
3.5 ± 2.1 
4.0 ± 2.5 
1.3±1.3 
2.3 ± 1.0 
Inhibition 
Percent 
51 
78 
88 
72 
" n = 4; incubation time, 3 n1in. 
ment for extracellular calcium was corroborated in experiments in 
which the buffer (HEPES-BSS lacking in calcium) was reconsti-
tuted with increasing concentrations of calcium (0, 1, 2, 3, 4, and 5 
mM). There was a calcium-dose-dependent increase in the release 
of histamine from CMC, reaching a plateau of net histamine release 
of 21.0 ± 1.0% at 2.0 mM calcium (Fig 4 ). Similarly, the presence 
of EDT A suppressed the net re lease of histamine induced by 4.0 J.lM 
A23187 from PMC from 28.8 ± 1.3% to 4.0 ± 2.8% (n = 3), a 
suppression of 86% (data not shown) . 
Effect of Purification Methods on Histamine Release In the 
above experiments, CMC were exposed to hyaluronidase and colla-
genase during extraction, whereas PMC were exposed to heparin. 
To evaluate the effect of these different reagents that of necessity 
were used in the extraction of CMC and PMC, CMC were incu-
bated with buffer containing 0.005% heparin during the first hour 
of enzymatic digestion; collagenase (1.5 mg/ml) and hyaluronidase 
(0.5 mg/ml) were added to the buffer used for peritoneal lavage of 
PMC. Stimulation of these CMC and PMC for 10 min with 
A23187 (3.0 J.lM for CMC, 4.0 J.lM for PMC) resulted in hista.mine 
releases that were of the same magnitude as those observed when the 
cells were extracted and purified in the regular manner (data now 
shown), suggesting that the differences observed were inherent 
properties of CMC and PMC rather than secondary to exposures to 
different reagents. 
25 
20 
15 
10 
5 
0 
0 1 2 3 4 5 
CONCENTRATION OF CALCIUM (mM) 
Figure 4. Effect of calcium on the histamine release from CMC induced by 
3.0 ,uM of A23187. A 3.0-min incubation was used (n = 3). 
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Figure 5. Dose-response analysis of compound 48/80-induced histamine 
release from mast cells of BALB/c mice. (A) Release from CMC with a 
3.0-min incubation (n = 3). (B) Release from PMC with a 10-min incuba-
tion (n = 3-7). 
Response to CMC and PMC to Compound 48/80 
Dose-Response Analysis: CMC released histamine in response to 
compound 48/80 in a dose-dependent fashion, reaching a plateau of 
0.5 ,ugjml of compound 48/80, with a net maximal release of 
23.0 ± 7.4% (Fig SA). In contrast, net histamine release induced by 
this secretagogue from PMC continued to increase at all the con-
centrations examined, with a net maximal release of 31.9 ± 2.6% at 
compound 48/80 of 10.0 ,ugjml, the highest concentration tested 
(Fig. 5B). 
Time-Course Analysis: The time course of histamine release in-
duced by compound 48/80 was performed with 2.0 ,ugjml for 
CMC and 1.0 ,ugjml for PMC. Maximal release was observed at 
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5 min for <:;Me,. with a net release of 16.3 ± 7.0% (Fig ?A). T~ 
release of 111Stamme from PMC reached peak levels at 1 mm, wit~ 
similar degree of release noted at all the time points tested ovel' 
10-min interval (Fig 6B). 
Response of CMC and PMC to Substance P (SP) 
Dose-Resporzse Analysis: SP is a neurogenic peptide known to i 
duce degranulation of human cutaneous and rat peritonea l mast ce~ 
[16, 17]. Maximal histamine release at 5.0 ,uM SP was noted for bo 
CMC and PMC, with net release of 18.8 ± 6.6% and 12.6 ± 3. 7 1Jt 
respectively (Fig 7 A,B). 1 
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Figure 6. Time course of compound 48/80-induced histamine releaJ 
from mast cell of BALB/c mice. (A} Release from CMC induced by 2.Q 
,Ugjml of compound 48/80 (n = 3). (B) Release from PMC induced by 1.Q 
f.tg/ml of compound 48/ 80 (n = 2 - 7). 
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Figure 7. Dose-response analysis of SP-induced histamine release from 
mas t cells ofBALB/c mice. (A) Release from CMC with a 3.0-min incuba-
tion (n = 4). (B) Release from PMC with a 30-min incubation (n = 3-7). 
Time-Course A11alysis: The time-course analys is of histamine re-
lease, using a 5.0 ,uM SP, showed different responses between CMC 
and PMC. Maximal net release of 18.2 ± 3.2% was noted at 
3.0 min for CMC (Fig. 8A), and maximal release of 11.4 ± 2.0% at 
30.0 min for PMC (Fig 8B). 
Requireme11t for Calcium: To evaluate the requirement for extracel-
lular calcium in histamine release induced by SP, experiments were 
performed in the presence of 1.0 mM of EDT A. As shown in Table 
IV, EDT A suppressed the release from CMC and PMC by 93% and 
41 o/o, respectively, indicating that although there was an absolute 
requirement for calcium in histamine release induced by SP from 
CMC, release from PMC was only partially calcium dependent. 
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Viability of CMC and PMC in the Presence of Secreta-
gogues To evaluate if histamine release in the presence of secreta-
gogues was due to alteration in mast-cell viability, the latter was 
examined. Identical incubation times were used as those in the dose-
response studies, and the highest concentration of the respective 
secretagogue was utilized. The viabilities of CMC following a 
3-min incubation at 37 •c with secretagogues were, for A23187 (10 
,uM), 89.8 ± 2.3%; for 48/80 (2.0 ,ug/ml), 94.0 ± 2.5%; and for SP 
(10 ,uM), 91.5 ± 4.0%. The viabilities for PMC following a 10-min 
incubation at 37•c with A23187 and 48/80 were A23187 (8 ,uM), 
94.3 ± 1.7%; and 48/80 (10 ,ug/ml) , 93.7 ± 2.4%. Following a 
30-min incubation of CMC with SP (100 ,uM), the viability was 
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Figure 8. Time-course analysis ofSP-induced histamine release from mast 
cel ls of BALB/c mice. (A} Release from CMC induced by 5.0 ,uM of SP 
(n = 11). (B) Release from PMC induced by 5.0 ,uM of SP (n = 3-6). 
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Table IV. Effect of EDT A (1.0 mM) on Net Histamine 
Release From Mast Cells Induced by SP• 
Percent Net Histamine Release 
SP Type of Inhibition 
(11M) Mast Cells Without EDTA With EDTA Percent 
5.0 CMC6 17.0±2.4 1.2 ± 0.8 93 
5.0 PMC' 14.3 ± 4.5 8.4 ± 2.9 41 
• For CMC, n = 5, incubation ti me is 5 min; for PMC, n = 3·, incubation time is 
30 min. 
'Cutaneous mast cel ls. 
' Peritoneal mast cells. 
96.9 ± 0.6%. The above viabilities were in the same magnitude as 
those observed in the presence of respective buffers, which were 
> 90%. 
DISCUSSION 
We report purification of functional CMC and PMC from BALE/ c 
mice to a purity of 68.6 ± 4.4% and 95.9 ± 0.6%, respectively . 
CMC were purified using a modification of techniques previously 
used to extract CMC from rats and humans [2,8) . In order to mini-
mize the leakage of histamine from CMC during extraction, buffers 
containing 25% FCS were used. To minimize the background his-
tamine release during subsequent procedures, 5% FCS was used in 
the buffers; this resulted in a background release of 11 .0 ± 1.0% 
while rendering the cells responsive to stimulation by secreta-
gogues. The method used to purify PMC was a modification of the 
method used previously by us to purify rat serosal mast cells [18). To 
minimize the background release, it was necessary to suspend the 
cells to TGD containing 0.5% BSA; this resulted in a background 
histamine re lease of 5.2 ± 0.8%, while still rendering the cells re-
sponsive to stimulation by secretagogues. 
Mouse ears were used as the source of cutaneous mast cells be-
cause in previous studies, a large number of dermal mast cells were 
observed histologically in ears, and they were the major source of 
elevated serum histamine in phototoxic responses and in allergic 
contact hypersensitivity responses [19,20) . Techn~cally, the tissue !s 
convenient to use because the ear has relatively httle hair and adi-
pose tissue, and the cartilage is easily removed. 
Calcium ionophore A23187 and compound 48/80 were sel.ected 
as secretagogues in this study because they ~re commonly usedm the 
study of mast-cell function. In humans, Intradermal mJeCt!On of 
compound 48/80 has been shown to induce a wheal and flare re-
sponse (21} . Substance P, a neurop~ptide, was al.so chosen ?ecauseit 
has been reported to be present 11~ human skm,. to parnctpate 111 
cutaneous inflammation, and to mduce histamme release from 
human cutaneous mast cells [22). N europeptides, including SP, 
have been postulated to play a role in the pathogenesis of cutaneous 
lesions of atopic dermatitis [23). . 
Studies on secretory response of CMC mduced by A23187 shows 
that C MC had a peak histamine release at 3.0 11M A23187 (Fig. 
1A), at 3.0 min (Fig 2A), and at 3o •c {Fig. ~A). The~e responses 
were very similar to the results reported previOusly usm.g human-
skin mast cells [8,12]. As compared to CMC, net his.taml1le rel~ase 
from PMC continued to increase even at 8.0 11M A23187, the htgh-
est concentration tested, and maximal histamine release was ob-
served at 15 min (Figs. 1B, and 2B). PMC ~esponded well through-
out the entire temperature range tested (Fig 3B). 
Of necessity, different reagents were used during the extraction 
of CM C and PMC, namely, hyaluronidase and collagenase were 
used for the former and heparin was used for the latter. To investi-
gate if the different responses of CMC and PMC ~ere due to ~he 
different extrac tion procedures used , CMC were mcubated wtth 
heparin , and PMC were incubated with hyaluronidase and colla-
genase during their respective purification steps. The fact th.at cells 
so treated responded in manners similar to those extracted usmg the 
regular methods suggests that the different responses observed be-
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tween CMC and PMC were due to heterogeneity of these eel[~ 
rather than to the extraction and purification procedures used. 
Similar functional heterogeneity of CMC and PMC in the dose 
response, time-course, and calcium-requirement experiments w~ 
also observed using compound 48(80 and SP as secretagogues. Fo~ 
example, although maximal net histamme release was noted wit~ 
5.0 ,uM SP for both CMC and PMC, peak release was achieveq 
WJthm 3.0 mm for the former and at 30.0 min for the latter. Th ere 
fore, taken to gether , the results of this study demonstrate for th~ 
first time that in BALB(c mice, heterogeneity exists between CM~ 
and PMC, both of whtch are constdered to be connecttve-tissu~ 
mast cells. These data support the concept that mast-cell heteroge\ 
neity ex1sts widely, not only between connective tissue m ast cell\ 
and mucosal mas t cells [12,16] , but also among the same type 0~ 
mast cells in different tissues or different locations [2,8]. Lowman e~ 
a\ [22) have extended the concept of mast-cell heterogeneity to "-
spectrum of mast cells, each one specialized to perform individua( 
~unctions within a particular ti ssue microenvironment. This theory 
ts supported by their different ultrastructures [24,25), different con •. 
tent of vasoactive amines and proteins [6,26], different numbers o~ 
IgE receptors on the cell surface [22), and different secretory func-
tional responses to secretagogues (6,8,12,16]. It has been demon-
strated that the same mast-cell precursor can differentiate into het-
erogeneous populations of mast cells in different local tissues 
[27,28] . Kitamura et al speculated that even in the same tissue the 
influence of the microenvironment might also' allow the dev; lop-
ment of more than one type of mast cell [29]. 
. In conc.lusion, methods are presented to extract and partially pu-
nfy functional CMC and PMC from BALB/c mice, which may be 
studied in vitro . Furthermore, functional heterogeneity was dem-
onstrated between these rwo types of mast cells. Because of the ease 
in obtaining cells from these animaJs, CMC ofBALB/c mice should 
serve as an ideal source for the study of cutaneous infl ammation. 
The authors wish to acknowledge the expert tecllllical assistattce of Ms. Regina 
Scotto-Ch i1111ici. 
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